CN111315364A - 用于持续递送抗血管生成肽的可生物降解微颗粒 - Google Patents

用于持续递送抗血管生成肽的可生物降解微颗粒 Download PDF

Info

Publication number
CN111315364A
CN111315364A CN201880039876.3A CN201880039876A CN111315364A CN 111315364 A CN111315364 A CN 111315364A CN 201880039876 A CN201880039876 A CN 201880039876A CN 111315364 A CN111315364 A CN 111315364A
Authority
CN
China
Prior art keywords
seq
microparticle
abu
peptide
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880039876.3A
Other languages
English (en)
Chinese (zh)
Inventor
乔丹·J·格林
尼兰詹·潘迪
亚历山大·S·波佩尔
彼得·A·坎波基亚罗
金滋荣
席尔瓦拉克尔·利马E
罗恩·史慕丽
亚当·米兰多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Asclepix Therapeutics Inc
Original Assignee
Johns Hopkins University
Asclepix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Asclepix Therapeutics Inc filed Critical Johns Hopkins University
Publication of CN111315364A publication Critical patent/CN111315364A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201880039876.3A 2017-05-08 2018-05-08 用于持续递送抗血管生成肽的可生物降解微颗粒 Pending CN111315364A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502913P 2017-05-08 2017-05-08
US62/502,913 2017-05-08
PCT/US2018/031663 WO2018208829A1 (en) 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide

Publications (1)

Publication Number Publication Date
CN111315364A true CN111315364A (zh) 2020-06-19

Family

ID=64104968

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880039876.3A Pending CN111315364A (zh) 2017-05-08 2018-05-08 用于持续递送抗血管生成肽的可生物降解微颗粒

Country Status (8)

Country Link
US (1) US20200179285A1 (https=)
EP (1) EP3621597A4 (https=)
JP (1) JP2020518651A (https=)
KR (1) KR20200003859A (https=)
CN (1) CN111315364A (https=)
AU (1) AU2018266690A1 (https=)
CA (1) CA3063140A1 (https=)
WO (1) WO2018208829A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222134A1 (zh) * 2022-05-20 2023-11-23 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021056B1 (pt) 2017-04-06 2022-11-22 Sustain Holdings, Llc Usos de uma composição que compreende um peptídeo mimético de colágeno para o tratamento ou a prevenção de uma doença, distúrbio ou ferida ocular
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
AU2020248438A1 (en) 2019-03-26 2021-10-28 Asclepix Therapeutics, Inc. Compositions and methods for treating ocular disease
EP3958889B1 (en) 2019-04-22 2025-01-08 Sustain Holdings, LLC Collagen mimetic peptide compositions for treating a posterior segment ocular disease or disorder involving the retina, retinal blood vessels, retinal nerves or optic nerve
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120114759A1 (en) * 2009-05-15 2012-05-10 The Johns Hopkins University Peptide/particle delivery systems
CN105431162A (zh) * 2013-06-07 2016-03-23 约翰霍普金斯大学 用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台
CN110177563A (zh) * 2016-10-04 2019-08-27 阿斯克雷佩西治疗公司 用于激活tie2信号传导的化合物和方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10314917B2 (en) * 2013-03-15 2019-06-11 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120114759A1 (en) * 2009-05-15 2012-05-10 The Johns Hopkins University Peptide/particle delivery systems
CN105431162A (zh) * 2013-06-07 2016-03-23 约翰霍普金斯大学 用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台
CN110177563A (zh) * 2016-10-04 2019-08-27 阿斯克雷佩西治疗公司 用于激活tie2信号传导的化合物和方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HONGYUN TAI: "《INTECH Open Access》", 1 February 2012 *
RAQUEL LIMA E SILVA等: "Tyrosine kinase blocking collagen IV–derived peptide suppresses ocular neovascularization and vascular leakage", 《SCIENCE TRANSLATIONAL MEDICINE》 *
RON B. SHMUELI等: "Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-deried peptide", 《BIOMATERIALS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222134A1 (zh) * 2022-05-20 2023-11-23 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用

Also Published As

Publication number Publication date
US20200179285A1 (en) 2020-06-11
WO2018208829A1 (en) 2018-11-15
KR20200003859A (ko) 2020-01-10
CA3063140A1 (en) 2018-11-15
WO2018208829A8 (en) 2019-07-04
JP2020518651A (ja) 2020-06-25
EP3621597A4 (en) 2021-06-02
EP3621597A1 (en) 2020-03-18
AU2018266690A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
CN111315364A (zh) 用于持续递送抗血管生成肽的可生物降解微颗粒
JP6600405B2 (ja) 新血管生成抑制のための血管内皮成長因子受容体ターゲッティングペプチド−エラスチン融合ポリペプチド及び自己組立ナノ構造体
US20130084277A1 (en) Formulations of active agents for sustained release
FI3884929T3 (fi) Tyrosiinikinaasi-inhibiittoria sisältävä silmäimplantti
WO1994027630A1 (en) Cross-linked gelatin gel preparation containing basic fibroblast growth factor
WO2006088650A2 (en) Method of treating eye injury with local administration of a vegf inhibitor
ES2699459T3 (es) Nanomatriz que imita endotelio
CN109072241A (zh) 具有改善的玻璃体内半衰期的组合物及其用途
CN110234336A (zh) 用于促性腺激素释放激素(GnRH)拮抗剂的长效释放的组合物和方法
KR20120130752A (ko) 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법
JP2015504098A (ja) 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
JP7626362B2 (ja) 中枢神経系に神経保護ポリペプチドを送達する方法
CN106794152A (zh) 用于预防角膜同种异体移植物排斥和新生血管形成的载有糖皮质激素的纳米颗粒
JP2020518651A5 (https=)
JP7650074B2 (ja) 眼疾患を治療するための組成物及び方法
Zaman et al. Carrier mediated systemic delivery of protein and peptide therapeutics
ES3010558T3 (en) Pharmaceuticals and devices for the covalent immobilization to the extracellular matrix by transglutaminase
Lee et al. Implantable devices to treat ophthalmic conditions: drug delivery systems
US20240226241A1 (en) Formulations for intraocular delivery of peptides derived from type iv collagen
AU2019270488B2 (en) Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
Hameed et al. Controlled Release of Therapeutic Proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200619

WD01 Invention patent application deemed withdrawn after publication